menu
    • menu
    [{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Jazz Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Extended Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Extended-Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Extended-Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Extended-Release Oral Suspension","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Extended Release Oral Solution","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Extended-release Oral Solution","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"GABA B receptor","graph1":"Sleep","graph2":"Preclinical","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.13,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Phase III","graph3":"Avadel Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ RTW Investments","highestDevelopmentStatusID":"10","companyTruncated":"Avadel Pharmaceuticals \/ RTW Investments"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Solution","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Oxybate","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avadel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avadel Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avadel Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sodium Oxybate

    Menu

    Sodium Oxybate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Announces FDA Approval of LUMRYZ™ For Narcolepsy in Patients 7 And Older

                            Details : Lumryz is an extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 17, 2024

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Announces First Patient Dosed in Phase 3 Trial of LUMRYZ for Idiopathic Hypersomnia

                            Details : Lumryz is an investigational, extended-release oral suspension formulation of sodium oxybate being investigated for the treatment of idiopathic hypersomnia.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2024

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amneal Launches Authorized Generic for Xyrem (sodium oxybate) and Receives FDA Approval for Five Complex Gener...

                            Details : sodium oxybate oral solution indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.

                            Brand Name : Xyrem-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 03, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Announces U.S. Commercial Launch of LUMRYZ (sodium oxybate) for the Treatment of Catapl...

                            Details : Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Announces Final FDA Approval of LUMRYZ™ (sodium oxybate) for Extended-Release Oral Su...

                            Details : Lumryz (sodium oxybate) is a once-nightly formulation of the USFDA approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 01, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Jefferies LLC

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

                            Details : The offering will be used for obtaining FDA approval of company's lead candidate, Lumryz, an investigational, extended-release formulation of sodium oxybate for the treatment of cataplexy or EDS in adults with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 29, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Jefferies LLC

                            Deal Size : $125.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : RTW Investments

                            Deal Size : $75.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

                            Details : The financing will support the potential commercialization of Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 29, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : RTW Investments

                            Deal Size : $75.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ Ahead of Anticipated ...

                            Details : Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 22, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) Extended Release Oral Suspen...

                            Details : Lumryz (sodium oxybate) is a sodium salt of GHB, a naturally occurring CNS depressant that increases dopamine levels and increases serotonin turnover. It is being developed for the treatment of cataplexy or excessive daytime sleepiness in adults with nar...

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 02, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Avadel Pharmaceuticals

                            Ireland arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Err...

                            Details : Lumryz (sodium oxybate) is a once-nightly formulation of the approved central nervous system depressant sodium oxybate in development for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.

                            Brand Name : Lumryz

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : Sodium Oxybate

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth